D. E. Shaw & Co. Inc. Sells 15,929 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

D. E. Shaw & Co. Inc. lowered its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 516,475 shares of the biopharmaceutical company's stock after selling 15,929 shares during the period. D. E. Shaw & Co. Inc. owned about 0.91% of Agios Pharmaceuticals worth $16,971,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in AGIO. Franklin Resources Inc. purchased a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $1,499,000. Contravisory Investment Management Inc. purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $222,000. Inspire Investing LLC raised its stake in shares of Agios Pharmaceuticals by 34.2% during the fourth quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company's stock worth $407,000 after acquiring an additional 3,156 shares in the last quarter. KBC Group NV lifted its holdings in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Agios Pharmaceuticals by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,092 shares of the biopharmaceutical company's stock valued at $397,000 after purchasing an additional 1,150 shares in the last quarter.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock opened at $29.14 on Tuesday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The firm has a market cap of $1.69 billion, a P/E ratio of 2.57 and a beta of 0.77. The business's 50 day moving average price is $29.14 and its 200-day moving average price is $37.06.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The business had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. As a group, equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on AGIO shares. Scotiabank decreased their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. Finally, HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.30% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.